BioEclipse Therapeutics focuses on developing immunotherapies for cancer treatment, specifically targeting solid tumors and enhancing patient responses through combined therapies involving immune cells and oncolytic viruses. The company is currently advancing its product, CRX100, through clinical trials.

BioEclipse Therapeutics

ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

Clare Murray

ElevateBio

Affimed is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies using its ROCK® (Redirected Optimized Cell Killing) platform.

Metric
Company Name	BioEclipse Therapeutics	ElevateBio	Affimed
Symbol
MSH ID	COM:BIOECLIPSE	BIO:ELEVATE	COM:AFFIMED
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	DE
Stage
Employee Count		462	105
Website	bioeclipse.com	elevate.bio	affimed.com
LinkedIn		elevatebio	affimed-ag
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOE

COM:BIOECLIPSE

BioEclipse Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue